Shannon McCall
Overview:
As Vice Chair for Translational Research in the Department of Pathology, I am involved in numerous translational cancer research projects that rely on the study of human biological samples. I am the director of the Duke BioRepository & Precision Pathology Center (Duke BRPC), a shared resource of the School of Medicine and the Duke Cancer Institute. I serve as the PI for the National Cancer Institute's Cooperative Human Tissue Network Southern Division (a five-year UM1 grant), which lives in the Duke BRPC. My own area of research interest is gastrointestinal tract metaplasias and their relationship to carcinogenesis, particularly in the upper GI tract.
Positions:
Associate Professor of Pathology
Pathology
School of Medicine
Associate Professor in Surgery
Surgery, Surgical Sciences
School of Medicine
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Education:
B.S. 1996
North Carolina State University
M.D. 2000
Duke University
Anatomic and Clinical Pathology, American Board of Pathology (ABPath)
American Board of Pathology
Clinical Informatics, American Board of Pathology (ABPath)
American Board of Pathology
Resident, Pathology
Duke University
Chief Resident, Pathology
Duke University
Grants:
Mutation analysis of pap smear samples and associated tissues for ovarian cancer diagnostics
Administered By
Pathology
Awarded By
Genendeavor LLC
Role
Principal Investigator
Start Date
End Date
Cooperative Human Tissue Network Support through Duke's BioRepository & Precision Pathology Center
Administered By
Pathology
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date
The genetics of hepatosplenic T cell lymphoma
Administered By
Medicine, Hematologic Malignancies and Cellular Therapy
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date
Lung Squamous Cell Carcinoma: Validation of Molecular Signatures of Prognosis
Awarded By
University of Colorado - Denver
Role
Pathologist
Start Date
End Date
Duke BRPC sub-contract with Leidos Biomed for NCI CPTAC III (Option1)
Administered By
Pathology
Role
Principal Investigator
Start Date
End Date
Publications:
Corrigendum: Psymberin, a marine-derived natural product, induces cancer cell growth arrest and protein translation inhibition.
[This corrects the article DOI: 10.3389/fmed.2022.999004.].
Authors
Dayanidhi, DL; Somarelli, JA; Mantyh, JB; Rupprecht, G; Roghani, RS; Vincoff, S; Shin, I; Zhao, Y; Kim, SY; McCall, S; Hong, J; Hsu, DS
MLA Citation
Dayanidhi, Divya L., et al. “Corrigendum: Psymberin, a marine-derived natural product, induces cancer cell growth arrest and protein translation inhibition.” Front Med (Lausanne), vol. 10, 2023, p. 1193745. Pubmed, doi:10.3389/fmed.2023.1193745.
URI
https://scholars.duke.edu/individual/pub1583662
PMID
37324143
Source
pubmed
Published In
Frontiers in Medicine
Volume
10
Published Date
Start Page
1193745
DOI
10.3389/fmed.2023.1193745
The Cooperative Human Tissue Network of the National Cancer Institute: Supporting Biomedical Research for Thirty-five Years
Authors
McCall, S; Chuaqui, R; Lubensky, I; Radin, K; Moskaluk, C; Ramirez, N; Parwani, A; Washington, M; LiVolsi, V
MLA Citation
McCall, Shannon, et al. “The Cooperative Human Tissue Network of the National Cancer Institute: Supporting Biomedical Research for Thirty-five Years.” Laboratory Investigation, vol. 103, no. 3, 2023, pp. S1555–S1555.
URI
https://scholars.duke.edu/individual/pub1584379
Source
wos-lite
Published In
Laboratory Investigation
Volume
103
Published Date
Start Page
S1555
End Page
S1555
Erratum to "Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy" [Eur Urol 2022;81(5):446-55].
Authors
MLA Citation
Cheng, Qing, et al. “Erratum to "Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy" [Eur Urol 2022;81(5):446-55].” Eur Urol, vol. 83, no. 6, June 2023, pp. e170–71. Pubmed, doi:10.1016/j.eururo.2023.03.019.
URI
https://scholars.duke.edu/individual/pub1572048
PMID
37012130
Source
pubmed
Published In
Eur Urol
Volume
83
Published Date
Start Page
e170
End Page
e171
DOI
10.1016/j.eururo.2023.03.019
Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer
<jats:p><p>Patient demographic are described in supplementary Table 1</p></jats:p>
Authors
Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Mantyh, CR; Hsu, DS
MLA Citation
Somarelli, Jason A., et al. Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. 3 Apr. 2023. Crossref, doi:10.1158/1535-7163.22521145.
URI
https://scholars.duke.edu/individual/pub1571796
Source
crossref
Published Date
DOI
10.1158/1535-7163.22521145
Supplementary Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer
<jats:p><p>Supplementary Figures</p></jats:p>
Authors
Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Mantyh, CR; Hsu, DS
MLA Citation
Somarelli, Jason A., et al. Supplementary Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. 3 Apr. 2023. Crossref, doi:10.1158/1535-7163.22521148.
URI
https://scholars.duke.edu/individual/pub1571797
Source
crossref
Published Date
DOI
10.1158/1535-7163.22521148
Research Areas:
Ampulla of Vater
Apoptosis
Bevacizumab
Bile Ducts
Biological Markers
Biopsy
Biopsy, Needle
Cell Differentiation
Cell Line
Cell Nucleus
Cell Proliferation
Cell Survival
Cells, Cultured
Colorectal Neoplasms
Colorectal Neoplasms, Hereditary Nonpolyposis
Cytochrome P-450 CYP2E1
Endocytosis
Epithelial Cells
Epithelial-Mesenchymal Transition
Gene Deletion
Gene Expression Profiling
Gene Expression Regulation
Gene Expression Regulation, Developmental
Gene Expression Regulation, Neoplastic
Genetic Predisposition to Disease
Hedgehog Proteins
Homeodomain Proteins
Humans
Hydroxyproline
Immunohistochemistry
Kruppel-Like Transcription Factors
Lasers
Mesenchymal Stromal Cells
Mesoderm
Microdissection
Mutation
Nuclear Proteins
Oligonucleotides, Antisense
Oligoribonucleotides, Antisense
Oncogenes
Organoplatinum Compounds
Pancreaticoduodenectomy
Pancreatitis
Pilot Projects
Prognosis
Protein Isoforms
Proteome
Proto-Oncogene Proteins
Proto-Oncogene Proteins B-raf
Pyrimidines
RNA, Messenger
Receptors, Cell Surface
Recombinant Proteins
Reverse Transcriptase Polymerase Chain Reaction
Signal Transduction
Stromal Cells
Thiazoles
Tissue Donors
Tumor Markers, Biological
Tumor Necrosis Factor-alpha
Wnt Proteins
Xenograft Model Antitumor Assays
ras Proteins

Associate Professor of Pathology
Contact:
Dept of Pathology Box 3712, Room 309 Davison Building, Durham, NC 27710
Duke Box 3712, Room 309 Davison Bldg, Durham, NC 27710